Figure 4.

HYPROGEN: Illuminating the genomic landscape of hypoxia-driven early metastatic prostate cancer: HYPROGEN is an exploratory biomarker driven study which will investigate hypoxia driven genomic instability in treatment naïve metastatic PCa patients. Patients will be treated with oral PIMO and samples will be taken from the primary tumour and its’ associated metastases. The trial will yield new ex-vivo models including organoids, circulating tumour cells and patient derived xenografts, as well as genomic data from untreated bone/lymph metastases and circulating tumour DNA. PCa, prostate cancer; PIMO, pimonidazole.